Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MRK

Merck & Co Inc

Dec 05 • 04:00PM ET

103.55

Dollar change +2.18
Percentage change 2.15	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE JNJ ABBV BMY AMGN LLY REGN GILD VRTX BHC

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM IWF VHT

Scroll to Statements

Index	DJIA, S&P 500	P/E	21.69	EPS (ttm)	4.77	Insider Own	0.09%	Shs Outstand	2.53B	Perf Week	0.42%
Market Cap	261.94B	Forward P/E	11.01	EPS next Y	9.40	Insider Trans	0.00%	Shs Float	2.53B	Perf Month	1.87%
Income	12.15B	PEG	0.77	EPS next Q	1.83	Inst Own	78.96%	Short Float	1.04%	Perf Quarter	-12.13%
Sales	62.89B	P/S	4.16	EPS this Y	413.08%	Inst Trans	0.01%	Short Ratio	2.47	Perf Half Y	-20.66%
Book/sh	17.58	P/B	5.89	EPS next Y	21.35%	ROA	10.83%	Short Interest	26.32M	Perf Year	-2.52%
Cash/sh	5.79	P/C	17.90	EPS next 5Y	28.00%	ROE	28.33%	52W Range	94.48 - 134.63	Perf YTD	-5.02%
Dividend Est.	3.10 (3.00%)	P/FCF	17.65	EPS past 5Y	-42.70%	ROI	15.28%	52W High	-23.09%	Beta	0.40
Dividend TTM	3.08 (2.97%)	Quick Ratio	1.15	Sales past 5Y	7.72%	Gross Margin	73.03%	52W Low	9.60%	ATR (14)	2.10
Dividend Ex-Date	Dec 16, 2024	Current Ratio	1.36	EPS Y/Y TTM	163.70%	Oper. Margin	23.00%	RSI (14)	55.51	Volatility	1.69% 2.16%
Employees	72000	Debt/Eq	0.86	Sales Y/Y TTM	8.17%	Profit Margin	19.32%	Recom	1.56	Target Price	130.53
Option/Short	Yes / Yes	LT Debt/Eq	0.79	EPS Q/Q	-33.34%	Payout	2065.60%	Rel Volume	1.04	Prev Close	101.37
Sales Surprise	1.11%	EPS Surprise	5.80%	Sales Q/Q	4.42%	Earnings	Oct 31 BMO	Avg Volume	10.64M	Price	103.55
SMA20	3.49%	SMA50	-1.10%	SMA200	-13.24%	Trades		Volume	11,031,643	Change	2.15%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115
Mar-06-23	Initiated	Jefferies	Buy	$125
Feb-22-23	Upgrade	Wolfe Research	Peer Perform → Outperform	$127
Jan-04-23	Upgrade	BofA Securities	Neutral → Buy	$110 → $130
Nov-18-22	Initiated	Credit Suisse	Outperform	$120
Oct-10-22	Upgrade	Guggenheim	Neutral → Buy
Sep-14-22	Upgrade	Berenberg	Hold → Buy	$95 → $100
Jul-06-22	Upgrade	Daiwa Securities	Neutral → Buy	$89 → $102

Show Previous Ratings

Today 01:45PM	Merck Earns Top Spot on Newsweek's List of America's Most Responsible Companies 2025 (ACCESSWIRE)
09:00AM	Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:48AM	Heres What is Powering Merck & Co.s (MRK) Earnings Growth (Insider Monkey)
06:45AM	Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults (Business Wire)
Dec-04-24 09:25AM	HSBC upgrades Merck stock to Buy on 2025 opportunities (Investing.com)
06:50AM	Loading…
06:50AM	Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan (TipRanks)
Dec-03-24 03:10PM	Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment (GuruFocus.com)
06:45AM	FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations (Business Wire)
Dec-02-24 07:46AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
07:13AM	Why Is Merck & Co., Inc. (MRK) Among the Stocks Ray Dalios Bridgewater Is Crazy About? (Insider Monkey)
Nov-26-24 09:11AM	Merck & Co. (MRK) Fell As It Faced Some Demand Headwinds In China (Insider Monkey)
06:50AM	Merck reports positive results from Phase 3 ZENITH trial evaluating Winrevair (TipRanks)
06:45AM	Merck to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-25-24 12:02PM	Why Is Merck Stock Trading Higher On Monday? (Benzinga)
06:57AM	New data could help Merck expand use of cardiovascular drug (BioPharma Dive)
06:45AM	Loading…
06:45AM	Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR (sotatercept-csrk) Met Primary Endpoint at Interim Analysis (Business Wire)
04:22AM	Merck & Co., Inc. (MRK): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-23-24 10:18AM	Hedge Funds Bet Big On Merck & Co. (MRK): Top Healthcare Stock to Watch (Insider Monkey)
10:18AM	Hedge Funds Bet Big On Merck and#038; Co. (MRK): Top Healthcare Stock to Watch (Insider Monkey)
06:30AM	U.S. FDA found asthma drug Singular, montelukast impacts the brain, Reuters says (TipRanks)
Nov-22-24 04:17PM	Merck Recommends Rejection of TRC Capitals Mini-Tender Offer (Business Wire)
09:00AM	Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know (Zacks)
07:15AM	Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
06:45AM	Mercks WELIREG (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors (Business Wire)
06:30AM	Surendralal Karsanbhai Elected to Merck Board of Directors (Business Wire)
06:19AM	Goldman Sachs: Merck & Co., Inc. (MRK) Is A Top Growth Investor Stock (Insider Monkey)
06:03AM	Exclusive-US FDA finds widely used asthma drug impacts the brain (Reuters)
Nov-21-24 06:45AM	Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities (Business Wire)
02:12AM	Keytruda represents almost half of Mercks sales, and a new formulation could fend off rivals (Pharma Voice)
Nov-20-24 03:10PM	Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care (ACCESSWIRE)
02:14PM	Loading…
02:14PM	Merck & Co., Inc. (MRK)s Blockbuster Drugs: A Key Player in Ken Griffins Portfolio (Insider Monkey)
Nov-19-24 01:17PM	Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients (Benzinga)
12:22PM	Merck Announces First-Quarter 2025 Dividend (Business Wire)
06:47AM	Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says (BioPharma Dive)
06:45AM	Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints (Business Wire)
Nov-18-24 06:00PM	Jim Cramer Says Merck & Co., Inc. (MRK) Is Just Way Too Hated' (Insider Monkey)
09:49AM	Is Merck & Co., Inc. (MRK) the Best Immunotherapy Stock to Buy Now? (Insider Monkey)
02:53AM	Why Merck rolled the dice on an unbelievable early-stage brain cancer drug (Pharma Voice)
12:44AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
Nov-15-24 04:18PM	How analysts are reacting to RFK Jr. as Trump's HHS pick (Yahoo Finance Video)
09:43AM	Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of. (Yahoo Finance)
07:15AM	Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM) (Business Wire)
Nov-14-24 04:54PM	Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics (Investor's Business Daily)
07:15AM	Merck to Participate in the Jefferies London Healthcare Conference (Business Wire)
06:45AM	Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. (Business Wire)
05:39AM	Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy (BioPharma Dive)
Nov-13-24 06:56AM	Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial (TipRanks)
05:26AM	MSD and AstraZeneca report positive topline data from Koselugo trial for NF1 (Clinical Trials Arena)
Nov-12-24 06:45AM	KOSELUGO (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial (Business Wire)
03:00AM	Merck to Present New Data From GARDASIL9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024 (Business Wire)
Nov-09-24 10:41AM	Merck & Co., Inc. (MRK): Among the Best Low Volatility Stocks to Invest In Now (Insider Monkey)
Nov-08-24 02:47PM	Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement (PR Newswire)
11:23AM	Why WEC Energy, Merck And Regions Financial Are Winners For Passive Income (Benzinga)
09:36AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
09:00AM	Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock (Zacks)
Nov-07-24 10:36AM	Merck & Co., Inc. (MRK) Makes It On UBS List Of Stocks For The AI, Growth & Low Rates Era (Insider Monkey)
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-06-24 06:45AM	Merck to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-04-24 06:41PM	Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy Right Now? (Insider Monkey)
Nov-01-24 02:33PM	Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease (Benzinga)
03:08AM	Merck & Co Inc (MRK) Q3 2024 Earnings Call Highlights: Strong Oncology and Animal Health ... (GuruFocus.com)
01:55AM	Q3 2024 Merck & Co Inc Earnings Call (Thomson Reuters StreetEvents)
Oct-31-24 04:12PM	Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales (Investor's Business Daily)
02:03PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
01:15PM	Merck (MRK) Q3 2024 Earnings Call Transcript (Motley Fool)
10:03AM	Bristol Myers Squibb stock rises, Merck moves lower. Here's why. (Yahoo Finance Video)
07:09AM	Merck earnings top estimates amid solid demand for Keytruda cancer drug (Investing.com)
06:37AM	Merck: Q3 Earnings Snapshot (Associated Press Finance)
06:35AM	Merck sees Gardasil China woes carrying into 2025 (Reuters)
06:30AM	Will Merck's Guidance Cut Prove Gruesome In The Wake Of Januvia, Gardasil Misses? (Investor's Business Daily)
06:30AM	Merck Announces Third-Quarter 2024 Financial Results (Business Wire)
Oct-30-24 12:44PM	Merck & Co., Inc. (MRK): A Bull Case Theory (Insider Monkey)
01:29AM	Jim Cramer Thinks That Merck & Co., Inc. (MRK) Is Too Low (Insider Monkey)
Oct-28-24 12:45PM	Why Is Moderna Stock Trading Higher On Monday? (Benzinga)
06:45AM	Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
Oct-27-24 08:58AM	Merck & Co., Inc. (MRK): Among the Best Dow Stocks to Buy According to Analysts (Insider Monkey)
01:39AM	Merck & Co., Inc. (MRK): Among the Best Stocks to Buy for High Returns in 2024 (Insider Monkey)
Oct-25-24 06:47PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
04:15PM	BetterInvesting Magazine Update on Merck (MRK) and Ball (BALL) (PR Newswire)
Oct-24-24 02:46PM	CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines (Benzinga)
01:42PM	US CDC AdCom recommends lowering the age for pneumococcal vaccines (Pharmaceutical Technology)
01:25PM	Merck (MRK): Patent Concerns and Earnings Forecast Cuts Impact Dow Performance (Insider Monkey)
10:01AM	Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:00AM	Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:45AM	Mercks KEYTRUDA (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers (Business Wire)
Oct-23-24 07:58PM	CDCS ACIP Recommends Mercks CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older (Business Wire)
03:35PM	800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio (Benzinga)
10:06AM	Is Merck & Co., Inc. (NYSE:MRK) the Most Undervalued Value Stock to Buy According to Analysts? (Insider Monkey)
07:45AM	Merck acquires cancer drug startup; Elevidys ex-US sales rise (BioPharma Dive)
Oct-22-24 05:50PM	Merck (MRK) Advances While Market Declines: Some Information for Investors (Zacks)
Oct-21-24 12:28PM	Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks (Benzinga)
Oct-20-24 03:00PM	Merck & Co. Inc. (MRK): Among the Best US Stocks for Foreign Investors Right Now (Insider Monkey)
Oct-19-24 05:09PM	Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 (Business Wire)
11:57AM	Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE (Insider Monkey)
Oct-18-24 04:46PM	MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win (Pharmaceutical Technology)
03:25PM	Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals (Insider Monkey)
08:08AM	Merck antibody reduces RSV-related disease, hospitalizations in trial (BioPharma Dive)
03:20AM	Merck & Co., Inc. (MRK): Among the Blue Chip Stocks With Low PE Ratios (Insider Monkey)
Oct-17-24 06:34PM	Is Merck & Co., Inc. (MRK) the Most Promising Long-Term Stocks According to Hedge Funds? (Insider Monkey)
06:00PM	Mercks Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants (Business Wire)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guindo Chirfi	Chief Marketing Officer	Aug 05 '24	Option Exercise	115.20	36,901	4,250,995	57,782	Aug 06 12:20 PM
Smart Dalton	SVP Fin. - Global Controller	May 03 '24	Option Exercise	128.26	2,046	262,420	4,708	May 06 04:10 PM
Smart Dalton	SVP Fin. - Global Controller	May 04 '24	Option Exercise	127.51	612	78,036	4,730	May 06 04:10 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 04 '24	Option Exercise	127.51	27,126	3,458,836	163,720	May 06 04:08 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 04 '24	Option Exercise	127.51	887	113,101	24,058	May 06 04:06 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 04 '24	Option Exercise	127.51	912	116,289	24,271	May 06 04:01 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '24	Option Exercise	128.80	2,262	291,346	21,831	May 02 04:29 PM
Smart Dalton	SVP Fin. - Global Controller	May 02 '24	Option Exercise	128.80	381	49,073	3,048	May 02 04:23 PM
Merck & Co., Inc.	10% Owner	Mar 11 '24	Buy	23.00	21,397,205	492,135,715	1,000	Mar 11 03:27 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Option Exercise	58.08	38,291	2,223,941	89,199	Feb 15 04:03 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Sale	125.50	38,291	4,805,520	50,908	Feb 15 04:03 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Option Exercise	74.18	150,000	11,127,160	498,327	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Option Exercise	73.73	85,021	6,268,598	433,348	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Sale	125.85	150,000	18,877,424	348,327	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Sale	125.40	85,021	10,661,574	348,327	Feb 15 04:01 PM
Romanelli Joseph	President, Human Health Int?l	Feb 13 '24	Sale	124.89	1,000	124,888	19,569	Feb 14 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Option Exercise	62.07	14,702	912,553	60,944	Feb 12 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Sale	125.50	14,702	1,845,083	46,242	Feb 12 04:03 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 07 '24	Sale	127.57	1,451	185,108	19,812	Feb 08 04:04 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Option Exercise	78.80	20,937	1,649,906	42,286	Feb 05 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Sale	127.17	18,959	2,411,111	23,327	Feb 05 04:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Option Exercise	73.65	32,994	2,430,159	74,313	Feb 02 04:07 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Sale	126.65	50,694	6,420,349	23,619	Feb 02 04:07 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Option Exercise	87.10	19,417	1,691,221	78,557	Feb 02 04:05 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Sale	126.97	49,499	6,284,779	29,058	Feb 02 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience